[EN] PROCESS FOR THE PRODUCTION OF AN IMMUNOSUPPRESSANT<br/>[FR] PROCEDE DE PRODUCTION D'UN IMMUNOSUPPRESSEUR
申请人:BIOCON LTD
公开号:WO2004020426A1
公开(公告)日:2004-03-11
The present invention discloses process of producing sodium salt of immuno-suppressant of formula I: (I)
本发明揭示了生产公式I的免疫抑制剂钠盐的工艺:(I)
[EN] MYCOPHENOLIC ACID BISMUTH SALT<br/>[FR] SEL DE BISMUTH A ACIDE MYCOPHENOLIQUE
申请人:BIOCON LTD
公开号:WO2005014567A1
公开(公告)日:2005-02-17
A compound, Tris 6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-, (4E)- 4-Hexenoic acid} bismuth salt of Formula (I), a process for its preparation, a composition containing the compound and a method of treatment using the compound.
Novel crystalline mycophenolate sodium polymorph and processes to manufacture same
申请人:Glass Chad
公开号:US20080176937A1
公开(公告)日:2008-07-24
The present invention includes the discovery of a novel polymorphic form of sodium mycophenolate (MPS) and processes for its formation. Furthermore, the present invention also includes a process to efficiently and cleanly convert the novel polymorphic form to known Form M2.
PROCESS FOR PREPARATION OF MYCOPHENOLIC ACID, ITS SALT AND ESTER DERIVATIVES
申请人:Kumar Ashok
公开号:US20110166347A1
公开(公告)日:2011-07-07
The present invention discloses an isolation and purification process for mycophenolic acid obtained from the fermentation process. Invention further discloses preparation of sodium salt of mycophenolic acid and mycophenolate mofetil from mycophenolic acid.
[EN] COMPOSITIONS AND METHODS FOR THE TREATMENT OF SARCOIDOSIS<br/>[FR] COMPOSITIONS ET MÉTHODES DE TRAITEMENT DE SARCOÏDOSE
申请人:INSMED INC
公开号:WO2017019636A1
公开(公告)日:2017-02-02
Compounds, methods, compositions and kits for treating a patient with pulmonary sarcoidosis are provided. The compositions are formulated for delivery to a patient in need of treatment via inhalation. In one embodiment, the method of treating pulmonary sarcoidosis in a patient in need thereof includes administering to the lungs of the patient via inhalation, a composition comprising an effective amount of a disease-modifying antisarcoid compound, a prodrug thereof, or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable inhalation excipient. The disease-modifying antisarcoid compound can be an immunomodulating agent, for example derivatives of mycophenolic acid, or a TNF-α antagonist.